Baiya’s co-founders have been interviewed by the press association Sky news about the topic of “Scientists in Thailand using tobacco leaves to develop plant-based vaccine to fight Omicron”.

“COVID-19 is not going to be the last one, right? You’re going to have so many emerging diseases and if we can develop the vaccine ourselves, then we don’t have to rely on vaccines from other countries,” explained co-founder and chief technology officer Dr.Waranyoo Phoolcharoen.

For more interview information please visit the link below;
https://news.sky.com/story/covid-19-scientists-in-thailand-using-tobacco-leaves-to-develop-plant-based-vaccine-to-fight-omicron-12502577

About Baiya Phytopharm
Baiya Phytopharm is a clinical-stage biopharmaceutical company, focused on strengthening health security for all people using the BaiyaPharming platform protein for therapeutics and vaccines. Baiya Phytopharm’s plant-based technology is a cutting-edge solution that is quick, simple, and scalable, aiming to replace biotech’s fermenter with plants. Our team combines deep technology expertise in plant biotech, pharmaceutical production professions and clinical development capabilities to create biologics candidates with high unmet medical needs of the ASIA-Pacific region. We have generated a broad proprietary portfolio of candidates including monoclonal antibodies for cancer or infectious disease and new vaccines for neglected tropical diseases.